Iambic Therapeutics, Inc (IAM) insider trading
Every open-market stock purchase and sale by Iambic Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Evan Lockwood Rachlin (Insider) bought $11.5M in the last 90 days, growing their stake 38%.
Last 12 months: insiders bought $11.5M (1 buy) and sold $0 (0 sales). Last close $15.80 on Oct 21, 2026.
Recent IAM insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Oct 16, 2026 | Evan Lockwood Rachlin (Insider) | Bought | $11.5M |
| Oct 16, 2026 | R Jacob Vogelstein (Insider) | Bought (not open market) | — |
| Oct 16, 2026 | R Jacob Vogelstein (Insider) | Bought (not open market) | — |
| Oct 16, 2026 | R Jacob Vogelstein (Insider) | Bought (not open market) | — |
| Oct 16, 2026 | R Jacob Vogelstein (Insider) | Bought (not open market) | — |
| Oct 16, 2026 | R Jacob Vogelstein (Insider) | Bought (not open market) | — |
| Oct 16, 2026 | R Jacob Vogelstein (Insider) | Bought (not open market) | — |
| Oct 16, 2026 | R Jacob Vogelstein (Insider) | Bought (not open market) | — |
| Oct 16, 2026 | Catalio Capital Management LP (10% owner) | Bought (not open market) | — |
| Oct 16, 2026 | Catalio Capital Management LP (10% owner) | Bought (not open market) | — |
| Oct 16, 2026 | Catalio Capital Management LP (10% owner) | Bought (not open market) | — |
| Oct 16, 2026 | Catalio Capital Management LP (10% owner) | Bought (not open market) | — |
| Oct 16, 2026 | Catalio Capital Management LP (10% owner) | Bought (not open market) | — |
| Oct 16, 2026 | Catalio Capital Management LP (10% owner) | Bought (not open market) | — |
| Oct 16, 2026 | Catalio Capital Management LP (10% owner) | Bought (not open market) | — |
| Oct 16, 2026 | Catalio Capital Management LP (10% owner) | Bought (not open market) | — |
| Oct 16, 2026 | Michael Secora (CFO) | Bought (not open market) | — |
| Oct 16, 2026 | Michael Secora (CFO) | Bought (not open market) | — |
| Oct 16, 2026 | William H Rastetter (Insider) | Bought (not open market) | — |
| Oct 16, 2026 | William H Rastetter (Insider) | Bought (not open market) | — |
| Oct 16, 2026 | William H Rastetter (Insider) | Bought (not open market) | — |
| Oct 16, 2026 | William H Rastetter (Insider) | Bought (not open market) | — |
| Oct 16, 2026 | William H Rastetter (Insider) | Bought (not open market) | — |
| Oct 16, 2026 | William H Rastetter (Insider) | Bought (not open market) | — |
| Oct 16, 2026 | William H Rastetter (Insider) | Bought (not open market) | — |
Who's trading IAM
- R Jacob Vogelstein, Insider: other filings, last Oct 16, 2026
- William H Rastetter, Insider: other filings, last Oct 16, 2026
- Evan Lockwood Rachlin, Insider: bought $11.5M (1 buy), last Oct 16, 2026
- Michael Secora, CFO: other filings, last Oct 16, 2026
- Catalio Capital Management LP, 10% owner: other filings, last Oct 16, 2026
- Peter A Olson, C-suite exec: other filings, last Oct 14, 2026
- Mary Tagliaferri, Insider: other filings, last Oct 14, 2026
- Shalini Sharp, Insider: other filings, last Oct 14, 2026
- Kurt Von Emster, Insider: other filings, last Oct 14, 2026
- Neil Josephson, C-suite exec: other filings, last Oct 14, 2026
- Frederick R Manby, CTO: other filings, last Oct 14, 2026
- Thomas F. Miller, CEO: other filings, last Oct 14, 2026
Get free alerts when an insider at Iambic Therapeutics, Inc files a new trade →